NASDAQ · CAMP
Healthcare · Biotechnology
$4.41
Down-$0.08 (-1.78%)
Updated Sep 7, 2026, 2:46 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CAMP does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning CAMP.
CAMP research
Company profile and research snapshot.
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | Piper Sandler | Overweight | — |
| Jun 16, 2026 | JP Morgan | Overweight | — |
| Jun 10, 2026 | Chardan Capital | Buy | — |
| Apr 14, 2026 | Rodman & Renshaw | Buy | — |
| Apr 2, 2026 | Leerink Partners | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 14, 2026
Piper Sandler analyst Edward Tenthoff reiterates Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight and raises the price target from $12 to $15.
Yahoo · Aug 13, 2026
CAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of +8.33% and +31.78%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Aug 13, 2026
Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this year. Received $50.1 million from fully subscribed second closing of private placement initially announced September 2025. Cash runway extended through the end of 2028. WATERTOWN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clin
Benzinga · Aug 13, 2026
Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.21) by 176.19 percent. This is a 6.45 percent increase over losses of $(0.62) per share
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CAMP.
